Loading…
No business profile yet.
Size Medcaptain Medical Technology (2041.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $412M, the 811th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$6.00 on 6 Nov 2026.
Growth Revenue grew 19.4% over the last twelve months (peer median +6.8%); the operating margin is 2.5% (peer median 5.7%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 5.0× (3rd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.5 points below its cost of capital (7.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.94B | HK$1.76B | HK$1.52B | HK$1.45B | HK$1.07B |
| Revenue growth | — | +16% | +5% | +36% | — |
| Gross profit | HK$1.06B | HK$943M | HK$754M | HK$720M | HK$466M |
| EBITDA | HK$190M | HK$189M | HK$18.8M | HK$13.1M | -HK$198M |
| Net income | HK$10.4M | HK$53.0M | -HK$105M | -HK$70.4M | -HK$259M |
| Free cash flow | HK$196M | HK$104M | HK$57.2M | -HK$33.3M | HK$16.8M |
| Capital expenditure | HK$99.4M | HK$107M | HK$146M | HK$99.7M | HK$110M |
| Total debt | HK$495M | HK$455M | HK$460M | HK$604M | HK$561M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2041.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.1% | -11.3% | 10th lowest of 21 |
| Distance from 52-week high | -45.0% | -40.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +19.4% | +6.8% | 5th highest of 20 |
| Operating margin | 2.5% | 5.7% | 9th lowest of 20 |
| EV / Sales | 1.6× | 5.0× | 3rd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 23.3% | 9.8% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +18.1% | +4.4% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | +5.3 pp | +6.2 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | -5.5 pp | -5.2 pp | 10th highest of 19 |
| EV / EBITDA | 16.5× | 12.3× | 3rd most expensive of 6 |
| Net debt / EBITDA | -0.5× | -2.1× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | 1.6× | 23.3% | +18.1% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 5.4× | 9.8% | +3.4% |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | 1.9× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 8.1× | 55.5% | +3.8% |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | 704.2× | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | 8.0× | n/a | n/a |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | 5.7× | n/a | n/a |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | 4.5× | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | 1.9× | -8.0% | -6.6% |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 1.5× | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 1.0× | -18.5% | +15.4% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | 5.5× | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 5.0× | 39.0% | +5.2% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | 7.8× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 4.4× | 11.8% | +5.6% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 6.0× | 20.0% | +4.4% |